• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Remmel H. Lawrence

    5/16/25 4:05:10 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATOS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Remmel H. Lawrence

    (Last) (First) (Middle)
    C/O ATOSSA THERAPEUTICS, INC.,
    10202 5TH AVE NE, SUITE 200

    (Street)
    SEATTLE WA 98125

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ATOSSA THERAPEUTICS, INC. [ ATOS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.99 05/15/2025 A 125,000 (1) 05/15/2035 Common Stock 125,000 $0 125,000 D
    Explanation of Responses:
    1. The options shall vest on a quarterly basis over 12 months following May 15, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued on May 15, 2025 with an exercise price of $0.99, representing the closing stock price on May 15, 2025.
    H. Lawrence Remmel 05/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ATOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

    Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025 Topline results anticipated in 2026  Positions Atossa for transition into registrational Phase 3 development SEATTLE, Aug. 20, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, announced today it has selected PSI, a leading global contract research organization (CRO), to operationalize and manage its planned (Z)-endoxifen monotherapy dose-ranging study in women with metastatic breast cancer (mBC). The study was designed following guidance from the U.S. Food and Drug Administration (FDA)

    8/20/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

    FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE, Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments. "Atos

    8/12/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

    SEATTLE, July 29, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced positive written feedback from the U.S. Food and Drug Administration (FDA) regarding the company's proposed dose optimization trial of (Z)-endoxifen for the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. With the FDA's feedback, Atossa is energized and moving quickly to advance (Z)-endoxifen in metastatic breast c

    7/29/25 7:45:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/22/25 6:27:25 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Finn Jonathan

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/16/25 4:05:23 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Steinhart Richard I

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/16/25 4:05:09 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    5/22/25 6:27:25 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    3/28/25 4:00:03 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

    4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)

    4/11/24 4:05:09 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    SEC Filings

    View All

    Atossa Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    8/21/25 4:05:28 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Atossa Therapeutics Inc.

    10-Q - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    8/12/25 8:45:46 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)

    8/12/25 8:40:29 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Leadership Updates

    Live Leadership Updates

    View All

    Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

    Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12

    11/12/24 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

    SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial

    11/5/24 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

    SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "We are excited to welcome Michael t

    8/20/24 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Financials

    Live finance-specific insights

    View All

    Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

    FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE, Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments. "Atos

    8/12/25 8:30:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

    Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication  Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.

    5/13/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

    Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre

    3/25/25 8:00:00 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/12/24 1:32:30 PM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    11/4/24 11:27:58 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Atossa Therapeutics Inc. (Amendment)

    SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)

    2/9/23 11:07:47 AM ET
    $ATOS
    Biotechnology: Pharmaceutical Preparations
    Health Care